Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

Rooney, Cliona M.; Ng, Catherine Y.; Loftin, Susan K.; Smith, Colton; Li, C; Krance, Robert A.; Brenner, Malcolm K.; Heslop, Helen E.

doi:10.1016/s0140-6736(95)91150-2

Cited by 1,106 publications

(674 citation statements)

References 24 publications

Supporting

Mentioning

659

Contrasting

Unclassified

Order By: Relevance

“…1, EBER-1, LMP have been used to identify patients at risk for PTLD, especially in the pediatric and allogeneic bone marrow transplant populations (11)(12)(13)(14)(15)(16). These two patient populations are particularly at high risk for PTLD, given the lack of EBV immunity in most pediatric patients and the high level of immunosuppression and the altered immune system seen in T-cell depleted or mismatched allogeneic bone marrow transplants.…”

Section: Ebv Pcr For Diagnosis and Monitoring Of Ptldmentioning

confidence: 99%

Use of EBV PCR for the Diagnosis and Monitoring of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients

Tsai

Nearey

Hardy

et al. 2002

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

Section: Ebv Pcr For Diagnosis and Monitoring Of Ptldmentioning

confidence: 99%

Use of EBV PCR for the Diagnosis and Monitoring of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients

Tsai

Nearey

Hardy

et al. 2002

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…There is increasing interest in immunotherapy for EBV-associated malignancies and adoptive transfer of in vitro activated EBV-specific CTL has proven effective for prevention and treatment of EBV-associated lymphoproliferative diseases after stem cell and organ transplants [9][10][11][12][13]. Extension of a similar strategy to other EBV-associated malignancies, such as HD [14] and NPC [15], has been reported to be efficacious in some patients.…”

Section: Introductionmentioning

confidence: 99%

Epstein‐Barr virus (EBV) latent membrane protein‐1‐specific cytotoxic T lymphocytes targeting EBV‐carrying natural killer cell malignancies

et al. 2006

View full text Add to dashboard Cite

Epstein‐Barr virus (EBV)‐encoded latent membrane protein (LMP) 1 is a potential target for immunotherapy of some proportion of Hodgkin's disease cases, nasopharyngeal carcinomas, EBV‐associated natural killer (NK)/T lymphomas, and chronic active EBV infection (CAEBV). Since it is unknown whether EBV‐infected NK/T cells are susceptible to lysis by LMP1‐specific cytotoxic T lymphohcytes (CTL), we here tested the ability of mRNA‐transduced antigen‐presenting cells (APC) to stimulate rare LMP1‐specific CTL. A 43‐amino acid N‐terminal deletion mutant LMP1 (ΔLMP1) could be efficiently expressed in dendritic cells and CD40‐activated B cells upon mRNA electroporation. ΔLMP1‐expressing APC were found to stimulate LMP1‐specific CTL from a healthy donor and a CTL clone recognized a peptide, IIIILIIFI, presented by HLA‐A*0206 molecules. Processing and presentation of the antigenic peptide proved dependent on expression of an immunoproteasome subunit, low‐molecular‐weight protein‐7, as confirmed by RNA interference gene silencing. Furthermore, an EBV‐infected NK cell line derived from a patient with CAEBV, and another from an NK lymphoma with enforced HLA‐A*0206 expression, were specifically lysed by the CTL. Overall, these data suggest that immunotherapy targeting LMP1 in EBV‐associated NK lymphomas and CAEBV might serve as an alternative treatment modality.

show abstract

“…[1][2][3][4] To obtain stable gene expression retroviral vectors are most frequently used for gene transfer. However, using standard supernatant infections with amphotropic vectors only low transduction efficiencies have been achieved.…”

mentioning

confidence: 99%

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements

et al. 1999

View full text Add to dashboard Cite

Current gene therapeutic protocols directed towards the vectors encoding a truncated human low-affinity nerve treatment of inherited disorders (eg ADA-SCID) and viral growth factor receptor (⌬LNGFR) as a gene transfer infections (eg AIDS), as well as adoptive immunotherapy marker, we obtained transduction frequencies of more than approaches are based on the use of genetically modified 70% of CD3 + cells after two cycles of infection. Our protolymphocytes. Since only insufficient transduction of T cells col is based on the use of FBS-free media for both the is obtained using existing techniques, the development of production of retrovirus-containing supernatant and the culmore efficient gene transfer protocols into these cells is of tivation of the primary T cells. Since the protocol presented great importance. We present here a protocol for the highly here works just as efficiently under large-scale conditions, efficient transduction of human primary T cells at high denit may be easily adapted to clinical needs and 'good manusities (1 × 10 6 /ml) by retroviral infection. Using retroviral facturing practice' (GMP) standards.

show abstract

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

Cited by 1,106 publications

References 24 publications

Use of EBV PCR for the Diagnosis and Monitoring of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients

Use of EBV PCR for the Diagnosis and Monitoring of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients

Epstein‐Barr virus (EBV) latent membrane protein‐1‐specific cytotoxic T lymphocytes targeting EBV‐carrying natural killer cell malignancies

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements

Contact Info

Product

Resources

About